Stay updated with breaking news from C Diff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.
November’s Gastroenterology Month in Review features an FDA approval, the discontinuation of a phase 3 clinical program, and news about Clostridioides difficile testing and risk factors.
Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.
A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.
Study finds that doxycycline, an antibiotic typically reserved as an alternative to azithromycin, is associated with reducing clostridioides difficile infections in pneumonia patients.